Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities

Recombinant human erythropoietin (rhEPO) is receiving increasing attention as a potential therapy for prevention of injury and restoration of function in nonhematopoietic tissues. However, the minimum effective dose required to mimic and augment these normal paracrine functions of erythropoietin (EP...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Coleman, Thomas R., Westenfelder, Christof, Tögel, Florian E., Yang, Ying, Hu, Zhuma, Swenson, LeAnne, Leuvenink, Henri G. D., Ploeg, Rutger J., d’Uscio, Livius V., Katusic, Zvonimir S., Ghezzi, Pietro, Zanetti, Adriana, Kaushansky, Kenneth, Fox, Norma E., Cerami, Anthony, Brines, Michael
Formato: Artigo
Idioma:Inglês
Publicado: National Academy of Sciences 2006
Assuntos:
Biological Sciences
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1458681/
https://ncbi.nlm.nih.gov/pubmed/16585502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0601377103
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares